WO2005103052A8 - Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof - Google Patents

Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof

Info

Publication number
WO2005103052A8
WO2005103052A8 PCT/IB2005/000991 IB2005000991W WO2005103052A8 WO 2005103052 A8 WO2005103052 A8 WO 2005103052A8 IB 2005000991 W IB2005000991 W IB 2005000991W WO 2005103052 A8 WO2005103052 A8 WO 2005103052A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pyrazolo
pyrimidin
cannabinoid
mediation
Prior art date
Application number
PCT/IB2005/000991
Other languages
French (fr)
Other versions
WO2005103052A1 (en
Inventor
David Andrew Griffith
Original Assignee
Pfizer Prod Inc
David Andrew Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, David Andrew Griffith filed Critical Pfizer Prod Inc
Publication of WO2005103052A1 publication Critical patent/WO2005103052A1/en
Publication of WO2005103052A8 publication Critical patent/WO2005103052A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The compounds of Formula (I) and (II) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.
PCT/IB2005/000991 2004-04-21 2005-04-11 Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof WO2005103052A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56464804P 2004-04-21 2004-04-21
US60/564,648 2004-04-21

Publications (2)

Publication Number Publication Date
WO2005103052A1 WO2005103052A1 (en) 2005-11-03
WO2005103052A8 true WO2005103052A8 (en) 2006-04-13

Family

ID=34963817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000991 WO2005103052A1 (en) 2004-04-21 2005-04-11 Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2005103052A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544191A1 (en) 2003-11-04 2005-05-26 Merck & Co., Inc. Substituted naphthyridinone derivatives
AU2005305675B2 (en) 2004-11-16 2012-12-13 Gw Pharma Limited New use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
JP4847275B2 (en) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 Pyrazolo [1,5-a] pyrimidine compounds
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
TW201345908A (en) * 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp A pyrazolo [1,5-a] pyrimidine compound
AR061793A1 (en) * 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp PIRAZOLO COMPOUND [1,5-A] PYRIMIDINE AND PHARMACEUTICAL COMPOSITION
JP4837701B2 (en) * 2007-04-20 2011-12-14 田辺三菱製薬株式会社 Pharmaceutical composition
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
BR112019003914A2 (en) * 2016-08-31 2019-05-28 Agios Pharmaceuticals Inc inhibitors of cellular metabolic processes
CN112921405B (en) * 2019-12-05 2023-06-27 成都先导药物开发股份有限公司 Method for synthesizing On-DNA pyrazolo [1,5-a ] pyrimidine compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527586A (en) * 2002-04-05 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド Substituted arylamides
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
WO2005103052A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
WO2005103052A8 (en) Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
MXPA05007562A (en) Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands.
CA2515596A1 (en) Cannabinoid receptor ligands and uses thereof
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
TW200716135A (en) Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
RS20050306A (en) Purine compounds and uses thereof as cannabinoid receptor ligands
MA29437B1 (en) IMIDAZOPYRIDAZINE COMPOUND
UA93043C2 (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
NO20053955D0 (en) Pyrazolo [1,5-A] pyrimidine derivatives
IL174475A0 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo['2,3-c]pyridin-2-ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
TW200510417A (en) Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4, 7-dione derivatives, processes for their preparation and their use as medicaments
TW200508235A (en) Substituted hexahydropyrazino[1, 2-a]pyrimidine-4, 7-dione derivatives, processes for their preparation and their use as medicaments
MX337817B (en) PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES.
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
PT1761542E (en) Octahydropyrrolo[3,4-c]pyrrole derivatives an their use as antiviral agents
TW200745121A (en) Chemical compound
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
IL174196A0 (en) 6-halogeno-[1,2,4]triazolo[1,5-a]pyrimidines for combating animal pests
WO2006033795A3 (en) Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
WO2006125178A3 (en) Tricyclic pyridazine compounds and their uses as therapeutic agents
PL1899343T3 (en) Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates
WO2004092171A3 (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
RS20050327A (en) Derivatives of /6,7-dihydro-5h- imidazo/1,2-alpha/imidazole- -3- sulfonylamino/-propionamide
SG152296A1 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase